See more : Friend Co.,Ltd. (605050.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NH Foods Ltd. (NIPMY) Income Statement Analysis – Financial Results
- Griffin Mining Limited (GFM.L) Income Statement Analysis – Financial Results
- We Win Limited (WEWIN.NS) Income Statement Analysis – Financial Results
- AusQuest Limited (AQD.AX) Income Statement Analysis – Financial Results
- Telo Genomics Corp. (TDSGF) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
| Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
| Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
| General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
| Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
| SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
| Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
| Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
| Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
| Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
| Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
| EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
| EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
| Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
| Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
| Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
| EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne...
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting .
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Source: https://incomestatements.info
Category: Stock Reports